LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 34 of 66
Next
>>
>
826 to 850 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Neratinib	180619_MC_12	16018	0.0225	101	262	4	9	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_7	363	0.0222	635.9	71.1	15071	356.7	0.0231	-0.00091	1.0269
Neratinib	180619_MC_12	15017	0.0244	120	250	8	15	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_8	370	0.0240	635.9	71.1	15071	356.7	0.0231	0.00097	0.9984
Neratinib	180619_MC_12	14600	0.0235	116	230	8	18	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_9	346	0.0232	635.9	71.1	15071	356.7	0.0231	0.00008	0.9861
Neratinib	180619_MC_10	3677	0.0310	66	50	11	14	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_1	116	0.0306	635.9	71.1	15071	356.7	0.0231	0.00751	0.4685
Neratinib	180619_MC_10	3349	0.0239	38	43	14	15	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_2	81	0.0236	635.9	71.1	15071	356.7	0.0231	0.00054	0.4388
Neratinib	180619_MC_10	3429	0.0271	41	53	14	18	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_3	94	0.0267	635.9	71.1	15071	356.7	0.0231	0.00361	0.4462
Neratinib	180619_MC_11	6448	0.0223	45	100	6	5	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_4	145	0.0220	635.9	71.1	15071	356.7	0.0231	-0.00108	0.6607
Neratinib	180619_MC_11	6157	0.0255	84	75	8	6	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_5	159	0.0252	635.9	71.1	15071	356.7	0.0231	0.00210	0.6440
Neratinib	180619_MC_11	7437	0.0280	94	117	9	5	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_6	211	0.0276	635.9	71.1	15071	356.7	0.0231	0.00451	0.7134
Neratinib	180619_MC_12	13596	0.0217	102	195	8	5	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_7	297	0.0214	635.9	71.1	15071	356.7	0.0231	-0.00170	0.9554
Neratinib	180619_MC_12	11193	0.0256	108	181	11	15	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_8	289	0.0252	635.9	71.1	15071	356.7	0.0231	0.00210	0.8739
Neratinib	180619_MC_12	12837	0.0191	87	160	12	7	Neratinib	0.099799997	treatment	72	2	MCF10A-GM_9	247	0.0189	635.9	71.1	15071	356.7	0.0231	-0.00420	0.9310
Neratinib	180619_MC_10	1225	0.0763	60	38	3	5	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_1	98	0.0741	635.9	71.1	15071	356.7	0.0231	0.05100	0.1544
Neratinib	180619_MC_10	1428	0.0684	64	38	10	8	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_2	102	0.0667	635.9	71.1	15071	356.7	0.0231	0.04359	0.1938
Neratinib	180619_MC_10	1268	0.0715	61	34	11	19	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_3	95	0.0697	635.9	71.1	15071	356.7	0.0231	0.04662	0.1631
Neratinib	180619_MC_11	1974	0.0457	61	32	3	22	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_4	93	0.0450	635.9	71.1	15071	356.7	0.0231	0.02192	0.2815
Neratinib	180619_MC_11	2602	0.0395	57	48	9	16	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_5	105	0.0388	635.9	71.1	15071	356.7	0.0231	0.01571	0.3614
Neratinib	180619_MC_11	2584	0.0442	65	52	14	9	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_6	117	0.0433	635.9	71.1	15071	356.7	0.0231	0.02024	0.3594
Neratinib	180619_MC_12	4180	0.0321	87	50	4	6	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_7	137	0.0317	635.9	71.1	15071	356.7	0.0231	0.00866	0.5103
Neratinib	180619_MC_12	3729	0.0453	114	60	5	17	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_8	174	0.0446	635.9	71.1	15071	356.7	0.0231	0.02151	0.4730
Neratinib	180619_MC_12	4158	0.0413	127	50	9	16	Neratinib	0.299399965	treatment	72	2	MCF10A-GM_9	177	0.0408	635.9	71.1	15071	356.7	0.0231	0.01776	0.5086
Neratinib	180619_MC_10	720	0.2028	64	95	10	3	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_1	159	0.1809	635.9	71.1	15071	356.7	0.0231	0.15781	0.0276
Neratinib	180619_MC_10	777	0.2529	85	133	10	21	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_2	218	0.2191	635.9	71.1	15071	356.7	0.0231	0.19602	0.0449
Neratinib	180619_MC_10	757	0.2776	93	143	11	20	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_3	236	0.2377	635.9	71.1	15071	356.7	0.0231	0.21459	0.0389
Neratinib	180619_MC_11	959	0.1657	79	93	3	12	Neratinib	0.997999609	treatment	72	2	MCF10A-GM_4	172	0.1521	635.9	71.1	15071	356.7	0.0231	0.12900	0.0941

|<
<<
Previous
Page 34 of 66
Next
>>
>
826 to 850 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)